



Figure S1. The antiviral activities of CCBs against SARS-CoV-2 in Huh7

Huh7 cells were treated with 10 μ M of indicated compounds and infected with SARS-CoV-2 at an MOI of 0.05, and at 24 hours p.i., supernatant was collected and cells were fixed. **(A)** Viral copy number in supernatant was measured with quantitative RT-PCT; **(B)** intracellular NP level was monitored with immunofluorescence. The experiments were done in triplicates, and data shown are means \pm SD. Bars: 400 μ m.

Table S1. Basic information and clinical characteristics of COVID-19 patients with hypertensive comorbidity.

	Total (n=96)	Amlodipine (n=19)	Non-amlodipine (n=77)	P
Female	45 (46.9)	12 (63.2)	33 (42.9)	0.112
Age, yr, IQR	66.5 (59-72)	65 (59-71)	67 (58.5-72.5)	0.751
Delay from symptom onset to admission	10 (7-15)	10 (7-15)	10 (7-15.5)	0.949
Symptoms at admission*				
Asymptomatic	2 (2.1)	1 (5.3)	1 (1.3)	0.358
Fever	66 (68.8)	10 (52.6)	56 (72.7)	0.091
Cough	59 (61.5)	11 (57.9)	48 (62.3)	0.722
Feeble	32 (33.3)	6 (31.6)	26 (33.8)	0.856
Chest distress	28 (29.2)	3 (15.8)	25 (32.5)	0.152
Shortness of breath	30 (31.3)	4 (21.1)	26 (33.8)	0.409
Anorexia	13 (13.5)	3 (15.8)	10 (13.0)	0.717
Nausea or vomiting	10 (10.4)	1 (5.3)	9 (11.7)	0.681
Diarrhea	16 (16.7)	4 (21.1)	12 (15.6)	0.514
Laboratory test results [#]				
WBC	5.77 (4.82-8.57)	7.32 (5.10-9.33)	5.63 (4.79-7.51)	0.276
PLT	212 (149-286)	270 (199-393)	207 (144-259)	0.081

Lymphocyte	0.82 (0.62-1.03)	0.82 (0.54-0.99)	0.82 (0.64-1.18)	0.764
Monocyte	0.42 (0.30-0.65)	0.43 (0.34-0.71)	0.42 (0.29-0.59)	0.536
Neutrophil	4.34 (3.28-6.51)	6.10 (3.58-7.72)	4.06 (3.21-5.95)	0.290
ALT	29 (20-55)	30 (22-45)	28.5 (20-56)	0.611
AST	33 (21-55)	28 (18-43)	34.5 (21-58)	0.422
ALB	34.0 (30.0-37.2)	34.8 (31.9-40.1)	33.9 (30.0-36.9)	0.057
GLB	33.9 (31.1-37.8)	33.3 (28.1-35.4)	34.2 (31.2-38.5)	0.246
TBIL	9.7 (7.4-13.9)	7.4 (6.1-8.8)	10.4 (8.0-14.3)	0.020
ALP	68 (57-84)	62 (53-70)	68 (57-92)	0.431
GGT	33 (21-69)	29 (23-56)	33 (20-71)	0.573
CK	89 (50-166)	114 (40-183)	87 (50-165)	0.856
LDH	321 (247-451)	293 (247-358)	325 (238-497)	0.101
CA	2.29 (2.20-2.42)	2.22 (2.18-2.35)	2.30 (2.20-2.44)	0.531
UREA	4.2 (3.3-6.5)	5.7 (4.1-6.6)	4.0 (3.2-6.4)	0.836
CR	75 (59-90)	80 (58-99)	73.5 (59-88.5)	0.397

*Clinical manifestations presenting before or at admission.

#Laboratory test results that were obtained at admission.

Table S2. Therapies administration during hospitalization in COVID-19 patients with hypertensive comorbidity.

	Total (n=96)	Amlodipine (n=19)	Non-amlodipine (n=77)	P
Antibiotics	96 (100)	19 (100)	77 (100)	1.000
Antiviral agents	96 (100)	19 (100)	77 (100)	1.000
Traditional Chinese medicines	77 (80.2)	17 (89.5)	60 (77.9)	0.347
Corticosteroids	46 (47.9)	8 (42.1)	38 (49.4)	0.571
Respiratory support	93 (96.9)	17 (89.5)	76 (98.7)	0.099